Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting

04:23 EDT 2 May 2013 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Women's Health
Latest News Clinical Trials Research Drugs Reports Corporate
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Obstetrics and gynaecology
Latest News Clinical Trials Research Drugs Reports Corporate
Obstetrics and gynaecology comprises the care of the pregnant woman, her unborn child and the management of diseases specific to women. Most consultants are generalists but the specialty offers a wide range of sub-specialties, which include materno-fetal...

Advertisement

Searches Linking to this Story